Product Description

Recombinant 2019-nCoV NSP8 is produced by our E.coli expression system and the target gene encoding Ala1-Gln198 is expressed with a 6His tag at the C-terminus.

Background:Cleavage by the viral main protease, 3CLpro results in generating the nsp8 protein, The nsp8 protein has been shown to associate with several other nsps and to colocalize with these nsps in cytoplasmic complexes that are important for viral RNA synthesis. It forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. Nsp8 was shown to have RNA-dependent RNA polymerase (RdRp) activity that could be involved in producing primers utilized by nsp12 which is normally accepted to be the RdRp for SARS-CoV.Formulation:Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 10% Glycerol, pH 8.5.Purity:> 95 % as determined by reducing SDS-PAGE.Endotoxin:< 1.0 EU per µg as determined by the LAL method.Shipping:This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at<-20°C. Avoid freeze-thaw cycles.

More Details:Sequence:Ala1-Gln198Fusion Tag:C-6HisAccession:YP_009725304.1Species:VirusExpression System:E. coliMol Mass:25 kDaAP Mol Mass:25 kDaSynonyms:SARS-CoV 2 nsp8Datasheet

FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES.Manufactured by: Elabscience

Questions about this product? Ready to place an order? Email us atorders@iwai-chem.comor give us a call: (650) 486-1541

Iwai-Chem我们的合作伙伴公司Bio Matrix Research，Inc.（BMR）正在申请专利，CELIXSYS™是一种新颖的单克隆抗体筛选方法（免疫沉淀等效系统），可保持抗原构象完整且表位不受空间位阻。  通过克服传统的基于固相的筛选方法（例如抗原包被的ELISA，斑点印迹或蛋白质印迹）的缺点，CELIXSYS™使我们能够获得适用于各种应用的卓越单克隆抗体，例如高灵敏度夹心ELISA，免疫色谱法或抗体阵列系统，以及免疫沉淀和蛋白质印迹。CELIXSYS™使得开发有益的单克隆抗体成为可能，而迄今为止，传统方法尚无法实现。展望未来，这项新技术的应用领域将继续从基础研究和临床诊断试剂扩展到抗体药物的探索。